glp 1 physiology informs the pharmacotherapy of obesity Frontiers Pharmacotherapy for obesity management—Emphasizing the

however, medications can affect metabolic pathways, therefore altering thyroid hormone production

For researchers already on tirzepatide who want to understand how it compares to the broader landscape, the phentermine versus GLP-1 comparison provides useful context, as does the Ozempic versus retatrutide analysis

The American Heart Association and Endocrine Society guidelines emphasize that stimulant-based appetite suppressants should not be used alongside incretin-based therapies due to unpredictable cardiovascular interactions

Similarly, in vivo studies based on rodents have shown reduced hepatic GHR expression (32) and GH binding (32, 33) following induction of diabetes, and that insulin treatment facilitated GH binding (33)